Yi Cheng

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Ke Cheng · 5 shared papers, 2020–2026 · strength 0.75
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
2. Wanting Hou · 3 shared papers, 2025–2026 · strength 0.64
   • Paper Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualita… DOI 10.1136/bmjopen-2024-084259↗
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
3. Chen Chang · 3 shared papers, 2022–2026 · strength 0.52
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
4. Dan Cao · 4 shared papers, 2020–2022 · strength 0.51
   • Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233↗
   • Paper Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemc… DOI 10.1186/s12885-020-07126-3↗
   • Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
5. Junjie Xiong · 3 shared papers, 2024–2026 · strength 0.51
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
6. Bole Tian · 3 shared papers, 2021–2026 · strength 0.46
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
   • Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
7. Zixing Huang · 2 shared papers, 2025–2026 · strength 0.36
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
8. Dan Cao · 2 shared papers, 2025–2026 · strength 0.36
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
9. Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
10. Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
11. Chenyan Zhang · 2 shared papers, 2025–2026 · strength 0.36
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
12. Lin Shui · 3 shared papers, 2020–2021 · strength 0.34
    • Paper Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemc… DOI 10.1186/s12885-020-07126-3↗
    • Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
    • Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
13. Xiaoying Li · 2 shared papers, 2024–2025 · strength 0.32
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
    • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
14. Rui Wang · 2 shared papers, 2024–2025 · strength 0.32
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
    • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
15. Ping Chen · 1 shared paper, 2025 · strength 0.28
    • Paper Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualita… DOI 10.1136/bmjopen-2024-084259↗
16. Shuangshuang Li · 2 shared papers, 2020–2021 · strength 0.23
    • Paper The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanc… DOI 10.1186/s12967-021-02972-6↗
    • Paper Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Pati… DOI 10.3389/fimmu.2020.01127↗
17. Hong Zhu · 2 shared papers, 2018 · strength 0.20
    • Paper Gemcitabine plus S-1 for metastatic pancreatic cancer. DOI 10.1097/md.0000000000012836↗
    • Paper A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in… DOI 10.1007/s00280-018-3658-9↗
18. Yi Zhang · 1 shared paper, 2026 · strength 0.19
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
19. Bing Peng · 1 shared paper, 2022 · strength 0.16
    • Paper A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Ret… DOI 10.1177/10732748221141233↗
20. Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
21. Yi Zhang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
22. Huanji Xu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
23. Bole Tian · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
24. Bo Chen · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
25. Heqi Yang · 1 shared paper, 2024 · strength 0.15
    • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.